The importance of integrating medication adherence into pharmacoeconomic analyses: The example of osteoporosis

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 2, 2012, Pages 159-166

  Hiligsmann, Mickal ^a,b   Boonen, Annelies ^a   Rabenda, Véronique ^b   Reginster, Jean Yves ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

adherence; compliance; cost effectiveness; economic; osteoporosis; persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB;

BONE DENSITY; CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; ECONOMIC EVALUATION; HUMAN; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; TREATMENT REFUSAL;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; ECONOMICS, PHARMACEUTICAL; FEMALE; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC;

EID: 84859478539     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.8     Document Type: Review

References (55)

1. Hughes D, Cowell W, Koncz T et al. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 10, 498-509 (2007). (Pubitemid 350013268)
2. Weycker D, Macarios D, Edelsberg J et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos. Int. 17, 1645-1652 (2006). (Pubitemid 44477625)
3. Kothawala P, Badamgarav E, Ryu S et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin. Proc. 82, 1493-1501 (2007). (Pubitemid 350211697)
4. Hiligsmann M, Rabenda V, Bruyere O et al. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 96, 170-177 (2010).
5. Hiligsmann M, Rabenda V, Gathon HJ et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif. Tissue Int. 86, 202-210 (2010).
6. Danese MD, Badamgarav E, Bauer DC. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. J. Bone Min. Res. 24, 1819-1826 (2009).
7. Landfeldt E, Lundkvist J, Strom O. The societal burden of poor persistence to treatment of osteoporosis in Sweden. Bone 48, 380-388 (2011).
8. Hiligsmann M, Gathon HJ, Bruyere O et al. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 13, 394-401 (2010).
9. Lekkerkerker F, Kanis JA, Alsayed N et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos. Int. 18, 1311-1317 (2007). (Pubitemid 47389473)
10. Cramer JA, Roy A, Burrell A et al. Medication compliance and persistence: terminology and definitions. Value Health 11, 44-47 (2008). (Pubitemid 351160875)
11. Siris ES, Selby PL, Saag KG et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am. J. Med. 122, S3-S13 (2009).
12. Cotte FE, Mercier F, De Pouvourville G. Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin. Ther. 30, 2410-2422 (2008).
13. Kanis JA, Cooper C, Hiligsmann M et al. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporos. Int. 22, 2563-2573 (2011).
14. Gold DT. Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. J. Manag. Care Pharm. 12, S20-S25 (2006). (Pubitemid 47400584)
15. Vermeire E, Hearnshaw H, Van Royen P et al. Patient adherence to treatment: three decades of research. A comprehensive review. J. Clin. Pharm. Ther. 26, 331-342 (2001). (Pubitemid 32989555)
16. Rabenda V, Reginster JY. Overcoming problems with adherence to osteoporosis medication. Expert Rev. Pharmacoecon. Outcomes Res. 10(6), 677-689 (2010).
17. Ross S, Samuels E, Gairy K et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 14, 571-581 (2011).
18. Imaz I, Zegarra P, Gonzalez-Enriquez J et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos. Int. 21, 1943-1951 (2010).
19. Siris ES, Harris ST, Rosen CJ et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin. Proc. 81, 1013-1022 (2006). (Pubitemid 44175011)
20. Briesacher BA, Andrade SE, Yood RA et al. Consequences of poor compliance with bisphosphonates. Bone 41, 882-887 (2007). (Pubitemid 47593009)
21. Rabenda V, Mertens R, Fabri V et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos. Int. 19, 811-818 (2008).
22. Landfeldt E, Strom O, Robbins S et al. Adherence to treatment of primary osteoporosis and its association to fractures - the Swedish adherence register analysis (SARA). Osteoporos. Int. 23, 433-443 (2012).
23. Gallagher AM, Rietbrock S, Olson M et al. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J. Bone Miner. Res. 23, 1569-1575 (2008).
24. Curtis JR, Larson JC, Delzell E et al. Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. Med. Care 49, 427-435 (2011).
25. Cadarette SM, Solomon DH, Katz JN et al. Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors. Osteoporos. Int. 22, 943-954 (2011).
26. Patrick AR, Schousboe JT, Losina E et al. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J. Clin. Endocrinol. Metab. 96, 2762-2770 (2011).
27. Hiligsmann M, Ethgen O, Bruyere O et al. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 12, 687-696 (2009).
28. Cotte FE, De Pouvourville G. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France. BMC Health Serv. Res. 11, 151 (2011).
29. Kanis JA, Adams J, Borgstrom F et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42, 4-15 (2008).
30. Ström O, Borgström F, Kanis JA et al. Incorporating adherence into health economic modelling of osteoporosis. Osteoporos. Int. 20, 23-34 (2009).
31. Jonsson B, Strom O, Eisman JA et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos. Int. 22, 967-982 (2011).
32. Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 29, 895-911 (2011).
33. Bone HG, Hosking D, Devogelaer JP et al. Ten years' experience with alendronate forosteoporosis in postmenopausal women. N. Engl. J. Med. 350, 1189-1199 (2004). (Pubitemid 38339363)
34. Bagger YZ, Tanko LB, Alexandersen P et al. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 33, 301-307 (2003). (Pubitemid 37103246)
35. Lo JC, Pressman AR, Omar MA et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos. Int. 17, 922-928 (2006). (Pubitemid 43781507)
36. Brookhart MA, Avorn J, Katz JN et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am. J. Med. 120, 251-256 (2007). (Pubitemid 46341156)
37. Schousboe JT, Taylor BC, Fink HA et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 298, 629-637 (2007). (Pubitemid 47236414)
38. Mueller D, Weyler E, Gandjour A. Cost effectiveness of the German screen-and-treat strategy for postmenopausal osteoporosis. Pharmacoeconomics 26, 513-536 (2008). (Pubitemid 351704859)
39. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38, 922-928 (2006). (Pubitemid 44498580)
40. Kendler DL, Bessette L, Hill CD et al. Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos. Int. 21, 837-846 (2010).
41. Cotte FE, Cortet B, Lafuma A et al. A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine 75, 201-208 (2008). (Pubitemid 351418261)
42. Cotte FE, Fautrel B, De Pouvourville G. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis. Med. Decis. Making 29, 125-139 (2009).
43. Earnshaw SR, Graham CN, Ettinger B et al. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Curr. Med. Res. Opin. 23, 2517-2529 (2007). (Pubitemid 350033454)
44. Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 102, 35-42 (2009).
45. Hiligsmann M, McGowan B, Bennett K et al. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland. Value Health (2012) (In press).
46. Vrijens B, Vincze G, Kristanto P et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 336, 1114-1117 (2008). (Pubitemid 351731741)
47. Breuil V, Cortet B, Cotte FE et al. Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos. Int. 23, 445-455 (2012).
48. Papaioannou A, Kennedy CC, Dolovich L et al. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 24, 37-55 (2007). (Pubitemid 46148080)
49. Hughes DA, Bagust A, Haycox A et al. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ. 10, 601-615 (2001). (Pubitemid 32998372)
50. Cleemput I, Kesteloot K, DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 59, 65-94 (2002). (Pubitemid 34098770)
51. Rosen AB, Spaulding AB, Greenberg D et al. Patient adherence: a blind spot in cost-effectiveness analyses? Am. J. Manag. Care 15, 626-632 (2009).
52. Cherry SB, Benner JS, Hussein MA et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 12, 489-497 (2009).
53. Breitscheidel L, Stamenitis S, Dippel FW et al. Economic impact of compliance to treatment with antidiabetes medication in Type 2 diabetes mellitus: a review paper. J. Med. Econ. 13, 8-15 (2010).
54. Salas M, Hughes D, Zuluaga A et al. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 12, 915-922 (2009).
55. Cleemput I, Kesteloot K, Vanrenterghem Y et al. The economic implications of non-adherence after renal transplantation. Pharmacoeconomics 22, 1217-1234 (2004). (Pubitemid 40075723)